During the past decade, Kanagawa Cardiovascular and Respiratory Center conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 19 clinical trials were completed, i.e. on average, 65.5% percent of trials that started reached the finish line to date. In the past 5 years, 12 clinical trials started and 15 clinical trials were completed. i.e. 125% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kanagawa Cardiovascular and Respiratory Center" #1 sponsor was "Boehringer Ingelheim" with 15 trials, followed by "Pfizer" with 4 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Actelion" with 2 trials sponsored and "Chugai Pharmaceutical" with 2 trials sponsored. Other sponsors include 8 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kanagawa Cardiovascular and Respiratory Center" #1 collaborator was "Eli Lilly and Company" with 4 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "NPO International TRI Network" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Kanagawa Cardiovascular and Respiratory Center" are "Idiopathic Pulmonary Fibrosis" (11 trials), "Lung Diseases, Interstitial" (4 trials), "Heart Failure" (3 trials), "Acute Myocardial Infarction" (2 trials) and "Autoimmune Pulmonary Alveolar Proteinosis" (2 trials). Many other conditions were trialed in "Kanagawa Cardiovascular and Respiratory Center" in a lesser frequency.

Most popular intervention types in "Kanagawa Cardiovascular and Respiratory Center" are "Drug" (33 trials), "Device" (3 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Nintedanib" (6 trials), "BI 1015550" (3 trials), "Carboplatin" (3 trials) and "Empagliflozin" (3 trials). Other intervention names were less common.

The vast majority of trials in "Kanagawa Cardiovascular and Respiratory Center" are 39 trials for "All" genders.

Currently, there are NaN active trials in "Kanagawa Cardiovascular and Respiratory Center". undefined are not yet recruiting, 7 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 26 completed trials in Kanagawa Cardiovascular and Respiratory Center, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Kanagawa Cardiovascular and Respiratory Center, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 27 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".